Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's ...

ORION CORPORATION PRESS RELEASE 30 JANUARY 2025 at 16.00 EET Orion and Invenra announce discovery service and commercial license agreement to develop innovative bispecific antibody ...

With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...

Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...

The soaring demand for antidiabetic and weight-loss drugs has lured in many biotech and big Pharma companies. Onto this ...

A serial entrepreneur and a promising drug emerge from failed companies to pursue subsets of obesity patients, with or ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Helicore, which is developing a GIP-blocking antibody, is the fourth obesity drug developer to receive funding from Versant ...

Two months after launching Pep2Tango Therapeutics, VC firm Versant Ventures is unveiling another obesity-focused biotech in ...

Japanese pharmaceutical company Eisai Co and U.S. firm Biogen Inc said Monday that a jointly developed Alzheimer's drug has been approved for continuous use for people with early stages of the disease ...

Biogen BIIB announced that the FDA has approved a monthly maintenance dosing version for its intravenously (IV) administered ...

K-Bio leaders pursue U.S. factories and conferences during Lunar New Year K-Bio executives opt for international business ...